Attovia is a pre-revenue biotech where insiders bought $68.4M (9.247% of market cap) while the shares sit in capitulation-style selling, 42% off their high, with quality below the engine's floor.
Thesis pillars
- Heavy Insider Buying→Stable
- Capitulation Momentum↑Improving
- Pre Revenue Cash Burn↑Improving
- +1 more pillar — see the Why tab for full reasoning
Attovia Therapeutics, Inc. (ATTO) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.73: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products... Read more
Sell if holding. Engine safety override at $13.73: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Score 4.9/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 24d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-19Recent Developments — Attovia Therapeutics, Inc.
Latest news
- NEWS Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress A — benzinga Sep 28, 2026 positive
- NEWS Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday — benzinga Sep 4, 2026 positive
- NEWS Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K — benzinga Sep 2, 2026 negative
- NEWS Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30 — benzinga Aug 31, 2026 positive
- NEWS LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45 — benzinga Aug 31, 2026 positive
Generated 2026-10-19T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.73: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Prior stop was $12.77. Score 4.9/10, moderate confidence.
Resistance target: $22.00 (+60.2% upside). Prior stop was $12.77. Stop-loss: $12.77.
DATA_ISSUE: analyst_target_implausible (raw $42.20 vs price $13.73 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (3.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (22 sells, 1.00% of cap).
Attovia Therapeutics, Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.0/10. Verdict: Sell.
What does Attovia Therapeutics, Inc. do?Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated...
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.